CDK4 and breast cancer: Three CDK4/6 inhibitors have recently received FDA approval for ER + breast cancer, including albociclib (PALBO) (Pfizer, FDA 2015), ribociclib (RIBO) (Novartis, FDA 2017), and abemaciclib (ABE) (Lilly, FDA 2017).